加载中
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
收盘时
US$21.84
−US$0.75 · -3.32%
盘后
US$21.64
−US$0.20 · -0.92%
10月12日 19:50 ET
盘中时间采用ET。市场数据可能有所延迟。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日内区间
当前US$21.84
52周区间
当前US$21.84
盘中时间采用ET。市场数据可能有所延迟。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日内区间
当前US$21.84
52周区间
当前US$21.84
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$52.60
上涨空间 140.84%报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI4518.03万0.46%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF3847.48万0.04%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB1130.67万0.10%108.2亿 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA825.58万0.04%218.24亿 USD0.03%US$32.66-0.40%
Vanguard Health Care ETFVHT766.19万0.03%220亿 USD0.09%US$320.67+0.52%
Invesco Dorsey Wright Healthcare Momentum ETFPTH298.62万1.04%2.87亿 USD0.74%US$58.3797-0.65%
Direxion Daily S&P Biotech Bull 3X SharesLABU219.03万0.34%6.49亿 USD0.96%US$231.99-4.57%
iShares Core S&P Total U.S. Stock Market ETFITOT201.83万0.00%980.88亿 USD0.03%US$169.43-0.14%State Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTInvesco Dorsey Wright Healthcare Momentum ETFPTHDirexion Daily S&P Biotech Bull 3X SharesLABUiShares Core S&P Total U.S. Stock Market ETFITOTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
